[1] Gu H. Recent advances in diagnosis and treatment of pulmonary hypertension[J]. Journal of Cardiovascular and Pulmonary Diseases, 2015, 34(7):594-596. (in Chinese)
顾虹. 最新肺动脉高压诊断与治疗进展[J]. 心肺血管病杂志, 2015, 34(7):594-596.
[2] Wang H, Lu YM. Progress in pathogenesis and treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease [J]. Journal of Clinical Pulmonary Medicine, 2015,20(11):2101-2103. (in Chinese)
王红, 陆月明. 慢性阻塞性肺疾病相关肺动脉高压发病机制及治疗进展[J]. 临床肺科杂志, 2015,20(11):2101-2103.
[3] Zhu ZhQ, Fan HN, Zhu DY. Progress in the study of the effects of hydrogen sulfide on cardiovascular diseases [J]. Medical Information, 2015,28(13):360. (in Chinese)
朱征全, 樊海宁, 朱丹燕. 硫化氢对心血管系统疾病影响的研究进展[J]. 医学信息, 2015,28(13):360.
[4] Li MX, Chen YH. Regulation mechanism and signaling pathway of hydrogen sulfide in pulmonary vascular remodeling[J]. Progress in Physiological Sciences, 2018,79(1):74-77. (in Chinese)
李敏霞, 陈亚红. 硫化氢在肺血管重塑中的调节机制及信号通路[J]. 生理科学进展, 2018,79(1):74-77.
[5] Han XH, Chen ZhL, Shi YW, et al. Research advance of p38MAPK in chronic hypoxia-induced pulmonary hypertension [J]. International Journal of Respiration, 2013, 33(11):865-867. (in Chinese)
韩小花, 程振玲, 施熠炜, 等. p38MAPK在慢性低氧性肺动脉高压中的作用研究进展[J]. 国际呼吸杂志, 2013, 33(11):865-867.
[6] Han T, Quan L, Hu TT, et al. Mechanisms of monocrotaline-induced right ventricular fatty acid metabolic disorder in rats with pulmonary hypertension[J]. Shandong Medical Journal, 2017, 57(33):29-31. (in Chinese)
韩婷, 权磊, 胡婷婷, 等. 野百合碱诱导肺动脉高压大鼠右心室脂肪酸代谢紊乱的机制[J]. 山东医药, 2017, 57(33):29-31.
[7] Zhang X, Wang YJ, Wang Q, et al. Effect of treprostinil on expression of inhibitor of differentiation in rat model with pulmonary arterial hypertension[J]. Journal of Jiangsu University (Medical Edition), 2016, 26(6):466-469. (in Chinese)
张霞, 王杨纪, 王骞, 等. 曲前列环素对大鼠肺动脉高压模型的治疗作用及其机制[J]. 江苏大学学报(医学版), 2016, 26(6):466-469.
[8] Rosenkranz S, Gibbs J, Wachter R, et al. Left ventricular heart failure and pulmonary hypertension[J]. Eur Heart, 2016, 37(12):942-954.
[9] Li HY, Yin ZT, Zhao KY. Effects of hydrogen sulfide on mast cell and IL-6 in rats with pulmonary hypertension induced by monocrotaline[J]. Chinese Journal of Laboratory Diagnosis, 2017,21(4):689-691. (in Chinese)
李红岩, 尹宗涛, 赵科研. 硫化氢对野百合碱诱导的肺动脉高压大鼠肥大细胞及IL-6的影响[J]. 中国实验诊断学, 2017,21(4):689-691.
[10]Li Zh, Li K, Chen YH. Research progress of endogenous hydrogen sulfide and the occurrence and development of cardiovascular diseases [J]. Chinese Circulation Journal, 2015,30(9):922-923. (in Chinese)
李贞, 李凯, 陈颖慧. 内源性硫化氢与心血管疾病发生发展的研究进展[J]. 中国循环杂志, 2015,30(9):922-923.
[11]Stenmark KR. Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms[J]. Circ Res, 2006, 99(7):675-691.
[12]Jin HF, Liang Ch, Liang JM, et al. Effects of hydrogen sulfide on vascular inflammation in pulmonary hypertension induced by high pulmonary blood flow:experiment with rats[J]. National Medical Journal of China, 2008, 88(32): 2235-2239. (in Chinese)
金红芳, 梁晨, 梁嘉敏, 等. 硫化氢对高肺血流性肺动脉高压大鼠血管炎症反应的调节作用[J]. 中华医学杂志, 2008, 88(32): 2235-2239.
[13]Shan F, Liu YJ, Cao YQ, et al. Effect of hydrogen sulfide on the expression of P47phox in hypoxic pulmonary hypertension rats[J]. Chinese Journal of Gerontology, 2017, 37(3): 571-572. (in Chinese)
单芳, 刘雨娟, 曹玉青, 等. 硫化氢对低氧性肺动脉高压大鼠P47phox表达的影响[J]. 中国老年学杂志, 2017, 37(3): 571-572.
[14]Church AC, Martin DH, Wadsworth R, et al. The reversal of pulmonary vascular remodeling through inhibition of p38 MAPK-alpha: a potential novel anti-inflammatory strategy in pulmonary hypertension[J]. Am J Physiol-Lung C, 2015, 309(4): L333-L347.
[15]Vanderpool RR, Tang H, Rischard F, et al. Is p38 MAPK a dark force in right ventricular hypertrophy and failure in pulmonary arterial hypertension[J]? Am J Resp Cell Mol, 2017, 57(5):506-508.
|